Guidance for industry: Immunogenicity assessment for therapeutic protein products [excerpts]

Biotechnology Law Report

Volumn 32, Issue 3, 2013, Pages 172-185

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879136885     PISSN: 0730031X     EISSN: None     Source Type: Journal    
DOI: 10.1089/blr.2013.9927     Document Type: Article

References (95)

1. Bachmann MF, Zinkernagel RM. 1997. Neutralizing antiviral B cell responses. Annu Rev Immunol 15:235-70.
2. Bachmann MF, et al. 1993. The influence of antigen organization on B cell responsiveness. Science 262(5138):1448-51.
3. Baert F, et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7):601-8.
4. Barandun S, et al. 1962. Intravenous administration of human gamma-globulin. Vox Sang 7:157-74.
5. Barbosa MD, Celis E. 2007. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today 12(15-16):674-81.
6. Bee JS, et al. 2009. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci 98(9):3290-301.
7. Bellomi F, et al. 2003. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci, 215(1-2):3-8.
8. Berkowitz SA. 2006. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J 8(3):E590-605.
9. Boven K, et al. 2005. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67(6):2346-53.
10. Braun A, Alsenz J. 1997. Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-alpha) formulations. Pharm Res 14(10):1394-400.
11. Bretthauer RK, Castellino FJ. 1999. Glycosylation of Pichia pastoris-derived proteins. Biotechnol Appl Biochem 30 (Pt 3):193-200.
12. Brockow K, Metcalfe DD. 2010. Mastocytosis. In: Chem Immunol Allergy. J. Ring, Editor. Karger: Basel, 111-124.
13. Carpenter JF, et al. 2009. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 98(4):1201-5.
14. Carrasco YR, Batista FD. 2007. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27(1):160-71.
15. Chung CH, et al. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358(11):1109-17.
16. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10(4):307-77.
17. Cole KS, et al. 2004. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120: results in redirection of B-cell responses to V3. J Virol 78(3):1525-39.
18. Dalum I, et al. 1997. Induction of cross reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol Immunol 34:1113-20.
19. De Groot AS, et al. 2008. Activation of natural regulatory T cells by IgG Fc-derived peptide tregitopes. Blood 112(8):3303-11.
20. Demeule B, Gurny R, Arvinte T. 2006. Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates. Eur J Pharm Biopharm 62(2):121-30.
21. Dharnidharka VR, et al. 1998. Membranous glomerulonephritis and nephrosis post Factor IX infusions in hemophilia B. Pediatr Nephrol 12(8):654-7.
22. Dintzis RZ, et al. 1989. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 143(4):1239-44.
23. Disis M, et al. 2004. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24:571-8.
24. Donnelly RP, Dickensheets H, O'Brien TR. 2011. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 32(9):443-50.
25. Duff GW. 2006. Expert Group on Phase One Clinical Trials: Final Report. GW Duff, Editor (accessible at www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-063117).
26. Ellis EF, Henney CS. 1969. Adverse reactions following administration of human gamma globulin. J Allergy 43(1):45-54.
27. Fotiou F, et al. 2009. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther 31(2):336-46.
28. Fradkin AH, Carpenter JF, Randolph TW. 2011. Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100(11):4953-64.
29. Franzke A, et al. 1999. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17(2):529-33.
30. Gamarra RM, et al. 2006. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 30(1):41-4.
31. Gamble CN. 1966. The role of soluble aggregates in the primary immune response of mice to human gamma globulin. Int Arch Allergy Appl Immunol 30(5):446-55.
32. Ghaderi D, et al. 2010. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 28(8):863-7.
33. Gogas H, et al. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709-18.
34. Gomord V, Faye L. 2004. Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol 7(2):171-81.
35. Goodnow CC. 1992. Transgenic mice and analysis of B-cell tolerance. Annu Rev Immunol 10:489-518.
36. Goto S, et al. 2009. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 89(3):305-9.
37. Gross PC, Zeppezauer M. 2010. Infrared spectroscopy for biopharmaceutical protein analysis. J Pharm Biomed Anal 53(1):29-36.
38. Hamilton JA. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8(7):533-44.
39. Haribhai D, et al. 2003. A threshold for central T cell tolerance to an inducible serum protein. J Immunol 170(6):3007-14.
40. Harris, JM, Martin NE, Modi M. 2001. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40(7):539-51.
41. Hellwig K, et al. 2008. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 65(5):656-8.
42. Hermeling S, et al. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21(6):897-903.
43. Hoffmann S, et al. 2008. HLA-DRB10401 and HLA-DRB10408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 83(2):219-27.
44. Hsu DH, et al. 1999. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation 68(4):545-54.
45. Huang L, et al. 2005. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 77(5):1432-9.
46. Hunley TE, et al. 2004. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 114(4):e532-5.
47. Inada Y, et al. 1995. Biomedical and biotechnological applications of PEG-and PM-modified proteins. Trends Biotechnol 13(3):86-91.
48. Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science 327(5963):291-5.
49. Kessler CM, Ortel TL. 2009. Recent developments in topical thrombins. Thromb Haemost 102(1):15-24.
50. Koren E. 2002. From characterization of antibodies to prediction of immunogenicity. Dev Biol 109:87-95.
51. Koren E, et al. 2008. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 333(1-2):1-9.
52. Lacana E, et al. 2012. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C Semin Med Genet 160(1):30-9.
53. Li J, et al. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98(12):3241-8.
54. Lieberman P, et al. 2010. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 126(3):477-80 e1-42.
55. Lin RY, et al. 2000. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 106(1 Pt 1):65-71.
56. Liu Y, et al. 2011. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J Pharmacol Toxicol Methods 64(3):238-45.
57. Ljung RC. 1995. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 94 Suppl 1:49-52.
58. Mahler HC, Jiskoot W. 2012. Analysis of Aggregates and Particles in Protein Pharmaceuticals. John Wiley & Sons, Inc. Hoboken, New Jersey.
59. Makrygiannakis D, et al. 2006. Citrullination is an inflammation- dependent process. Ann Rheum Dis 65(9):1219-22.
60. Mendelsohn NJ, et al. 2009. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 360(2):194-5.
61. Messinger YH, et al. 2012. Successful immune tolerance induction to enzyme replacement therapy in CRIMnegative infantile Pompe disease. Genet Med 14(1):135-42.
62. Miller LL, et al. 1999. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood 93(10):3250-8.
63. Morefield GL, et al. 2005. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13):1588-95.
64. Murphy K. 2011. The Humoral Immune Response. In Janeway's Immunobiology. Garland Science Publishing: New York, 367-408.
65. Norman DJ, et al. 2000. Phase I trial of HuM291, a humanized Anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 70(12):1707-12.
66. Oldenburg J, et al. 2004. Environmental and genetic factors influencing inhibitor development. Semin Hematol 41(1 Suppl 1):82-8.
67. Ragnhammar P, et al. 1994. Induction of Anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84(12):4078-87.
68. Roda B, et al. 2009. Field-flow fractionation in bioanalysis: a review of recent trends. Anal Chim Acta 635(2):132-43.
69. Romer PS, et al. 2011. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118(26):6772-82.
70. Rosenberg AS, Worobec A. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products 2: considering host-specific and product-specific factors impacting immunogenicity. BioPharm International 17(12):34-42.
71. Rosenberg AS, Worobec A. 2005. A risk-based approach to immunogenicity concerns of therapeutic protein products 3: effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. BioPharm International 18(1):32-6.
72. Sampson HA, et al. 2006. Second Symposium on the Definition and Management of Anaphylaxis: Summary Report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117(2):391-7.
73. Sanz ML, et al. 2010. In vitro diagnosis of anaphylaxis. Chem Immunol Allergy 95:125-40.
74. Seong SY, Matzinger P. 2004. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4(6):469-78.
75. Shanmugam G, Schwartz LB, Khan DA. 2006. Prolonged elevation of serum tryptase in idiopathic anaphylaxis. J Allergy Clin Immunol 117(4):950-1.
76. Sharp FA, et al. 2009. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 106(3):870-5.
77. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-402.
78. Simons FE. 2008. Anaphylaxis. J Allergy Clin Immunol 121(2 Suppl):S402-7.
79. Simons FE. 2009. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol 124(4):625-36.
80. Simons FE, et al. 2007. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 120(1 Suppl):S2-24.
81. Stebbings R, et al. 2007. Cytokine storm in the Phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179(5): 3325-31.
82. Tatarewicz SM, et al. 2007. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving R-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 27(6):620-7.
83. Tovey MG, Lallemand C. 2010. Adjuvant activity of cytokines. In Methods in Molecular Biology. G. Davies, Editor. Springer Science 626:287-309.
84. Verthelyi D, Wang V. 2010. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS One 5(12):e15252.
85. Viel KR, et al. 2009. Inhibitors of Factor VIII in black patients with hemophilia. N Engl J Med 360(16):1618-27.
86. Wakankar AA, Borchardt RT. 2006. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 95(11):2321-36.
87. Wang J, et al. 2008. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 26(8):901-8.
88. Warrier I, et al. 1997. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 19(1): 23-7.
89. Weber CA, et al. 2009. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev 61(11):965-76.
90. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422(6929):307-12.
91. Weigle WO. 1980. Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis. Adv Immunol 30:159-273.
92. White PJ, et al. 2008. Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants. Vaccine 26(52):6824-31.
93. Worobec A, Rosenberg AS. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products 1: considering consequences of the immune response to a protein. BioPharm International 17(11):22-6.
94. Wyatt Technology, n.d Understanding Laser Light Scattering Theory (accessible at www.wyatt.com/theory/theory/ understandinglaserlightscatteringtheory.html)
95. Xiang SD, et al. 2008. Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 7(7): 1103-19.